Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00650702 · ClinicalTrials.gov registry record · Phase 2

Safety and Efficacy of Punctum Plug Delivery System in Subjects With Open-Angle Glaucoma or Ocular Hypertension

A Phase 2 study, sponsored by Mati Therapeutics.

Completed
Registry status
Phase 2
Development phase
36
Enrollment target

NCT00650702: Completed Phase 2 study, sponsored by Mati Therapeutics.

NCT00650702 is a Phase 2 study that has completed, run by Mati Therapeutics. The registered enrollment target is 36 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00650702, a Phase 2 study, has completed, sponsored by Mati Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
36 participants
Enrollment target

Study Summary

The purpose of this study is to determine if the Punctum Plug Delivery System (PPDS) is safe and effective in controlling intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Interventions

  • DRUG Latanoprost-PPDS

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2008-03
Est. Completion 2009-02
Phase Phase 2
Mati Therapeutics

12 total trials

What the finished NCT00650702 record still lists

NCT00650702 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower).

The record links to 0 conditions, and to 1 intervention - of which Latanoprost-PPDS is the first listed.

NCT00650702 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00650702 about?

NCT00650702 is a clinical study titled "Safety and Efficacy of Punctum Plug Delivery System in Subjects With Open-Angle Glaucoma or Ocular Hypertension". The purpose of this study is to determine if the Punctum Plug Delivery System (PPDS) is safe and effective in controlling intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

What is the current status of trial NCT00650702?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2008-03. Estimated completion is 2009-02.

What interventions are being tested in trial NCT00650702?

The interventions under investigation include: Latanoprost-PPDS (DRUG).

Who is sponsoring clinical trial NCT00650702?

This trial is sponsored by Mati Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00650702's enrollment target sits among peer trials

36 1496th of 2000 higher than 477 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00929006 · 36 participants · Early Phase 1

    Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

  • NCT01891318 · 36 participants · Phase 1

    Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

  • NCT02291848 · 36 participants · Phase 1

    Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

  • NCT02366819 · 36 participants · Phase 4

    Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00650702, the US trial registry maintained by the National Library of Medicine. NCT00650702 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.